Premium
The CONSORT statement checklist in allergen‐specific immunotherapy: a GA 2 LEN paper
Author(s) -
Bousquet P. J.,
Brozek J.,
Bachert C.,
Bieber T.,
Bonini S.,
Burney P.,
Calderon M.,
Caica G. W.,
Compalati E.,
Daures J. P.,
Delgado L.,
Demoly P.,
Dahl R.,
Durham S. R.,
Kowalski M. L.,
Malling H. J.,
Merk H.,
Papadopoulos N.,
Passalacqua G.,
Simon H. U.,
Worms M.,
Wahn U.,
Zuberbier T.,
Schünemann H. J.,
Bousquet J.
Publication year - 2009
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2009.02232.x
Subject(s) - consolidated standards of reporting trials , blinding , checklist , medicine , randomized controlled trial , context (archaeology) , placebo , adverse effect , inclusion and exclusion criteria , psychological intervention , clinical trial , family medicine , allergen immunotherapy , alternative medicine , intensive care medicine , allergen , allergy , psychology , immunology , nursing , pathology , paleontology , cognitive psychology , biology
The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen‐specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo‐controlled Phase III studies in this article. Our analysis focuses on the definition of patients’ inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.